Article Category: Original Paper
Published Online: Apr 04, 2022
Page range: 1 - 8
Received: Aug 06, 2021
Accepted: Nov 05, 2021
DOI: https://doi.org/10.2478/afpuc-2022-0001
Keywords
© 2022 S. Kosirova et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
AIM
The aim of the study was to evaluate cardiovascular risk in patients with diabetes mellitus type 2 according to gender.
METHODS
The monitoring was designed as a retrospective analysis of data obtained from the documentation of the diabetic outpatients treated with the dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose co-transporter-2 (SGLT2). Cardiovascular risk was assessed according to UKPDS risk engine.
RESULTS
The levels of HbA1c decreased throughout the whole study. Sixty per cent of patients achieved an HbA1c level <8% after 18 months. Both men and women had similar glycaemic compensation. Men had a significantly higher risk of fatal coronary heart disease (CHD) (
CONCLUSION
Potential cardiovascular effects of antidiabetic treatment should be clearly defined with possible different effects according to gender. We found a much higher risk in men than women, even when their glycaemic compensation was comparable.